Eli Lilly’s Experimental Weight Loss Drug Shows Promise in Diabetes Trial

Pharmaceutical giant Eli Lilly announced promising results from a clinical trial of its experimental obesity medication, retatrutide. The drug demonstrated significant blood sugar improvements and weight loss in patients with type 2 diabetes during a 40-week study.

Pharmaceutical company Eli Lilly announced Thursday that its experimental weight loss medication demonstrated significant improvements in blood sugar control during advanced clinical testing, as the company seeks to strengthen its position in the competitive obesity treatment market.

The booming weight loss drug industry has attracted numerous developers competing against established treatments like Novo Nordisk’s Wegovy and Lilly’s own Zepbound. Companies are investing heavily in advanced therapies that could provide more effective, longer-lasting, or faster weight reduction results.

The experimental medication, called retatrutide, was evaluated in people with type 2 diabetes who struggled to manage their blood sugar through diet and exercise alone. Study participants had been living with diabetes for an average of two and a half years.

Throughout the 40-week study period, retatrutide lowered A1C levels—a standard measurement of blood sugar over time—by 1.7% to 2.0% on average across different dosages. In comparison, participants receiving a placebo saw only a 0.8% average reduction.

As an additional benefit, patients using the medication experienced weight loss averaging up to 16.8% of their body weight.

The company reported that adverse effects were consistent with what researchers typically observe in weight loss studies, primarily digestive problems including nausea, diarrhea, and vomiting.

Earlier research showed retatrutide helped participants achieve an average weight reduction of 28.7%, surpassing the performance of Lilly’s successful medication Zepbound.

Administered as a weekly injection, retatrutide works by copying the function of the GLP-1 hormone, which plays a role in managing blood sugar levels, slowing digestion, and reducing hunger.

The medication targets three different hormone receptors—GLP-1, GIP, and glucagon—which has earned it the informal name “triple G.” These triple-action weight loss treatments are anticipated to achieve superior results compared to earlier medications by simultaneously suppressing appetite, controlling blood sugar, and boosting calorie expenditure.

Lilly is simultaneously working on orforglipron, a weight loss medication in pill form, which the company anticipates launching in the second quarter of this year pending U.S. Food and Drug Administration approval.